Previous 10 | Next 10 |
home / stock / bmymp / bmymp news
Monthly update of the Dividend Champions List. 55 companies declared higher dividends in the past month, with an average increase of 6.1% over their previous payouts. One new Champion, ten new Contenders, and seven new Challengers. For further details see: Dividend Champ...
C4 Therapeutics, along with a host of others, is developing therapeutics in the cutting edge field of protein degraders. Blockbuster drugs like Revlimid and Pomalyst are now known to be protein degraders. In preclinical trials, C4's molecule has done better than Pomalyst in MM xen...
A weekly summary of dividend activity for Dividend Champions and Contenders. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. For further details see: Dividend Champion And Contender Highlights: We...
2020 was a dumpster fire of a year, in more ways than one. I review the pivotal arguments and points I made on Seeking Alpha in 2020. I also give an all-too-rare review of my overarching investment philosophy and goal: achieving financial freedom through passive income. Lastly, I ...
Wedgewood Partners’ 13F portfolio value increased from $590M to $632M this quarter. David Rolfe added First Republic Bank and doubled Microsoft while dropping Nvidia. Their top five positions are at 39% of the overall portfolio. For further details see: Tracking D...
AstraZeneca has announced its acquiring Alexion at a fairly substantial 45% premium. It's a mixed stock - cash offer. The synergies will cover most of the ~$900 million in annual dividend / interest costs with significant growth potential. AstraZeneca is working to position itself...
A weekly summary of dividend activity for Dividend Champions and Contenders. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. For further details see: Dividend Champion And Contender Highlights: We...
Halvorsen's 13F portfolio value increased from $23.14B to $27.68B. The number of positions increased 71 to 86. Viking Global increased Microsoft, Mecadolibre, and CME Group while reducing Amazon.com and dropping Uber Technologies & JD.com. The top three positions are Microsoft...
The contingent value right issued to Celgene shareholders after the Bristol-Myers acquisitions are dependent on approval of Liso-cell and Ide-cell. For Liso-cell to be approved the FDA seems insistent on inspection of a Texas-based Lonza facility. Twitter sources point toward a ph...
My portfolio produced total returns of 11.2% in November. Year-to-date, I am up 17.95% through the first 11 months of the year. My passive income was up 26.61% in November. Year-to-date, my passive income is up 11.66%. For further details see: Nicholas Ward's Dividen...
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb $2Pr Company Name:
BMYMP Stock Symbol:
OTCMKTS Market:
Bristol-Myers Squibb $2Pr Website: